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Abstract
Molecular analyses have demonstrated mutations in
the K-ras gene at codon 12 in the majority of pan-
creatic ductal adenocarcinomas (PDACs). In order to
determine whether the K-ras mutation rate increases
parallel to the grade of dysplasia in duct lesions, we
performed a meta-analysis of the studies published
between 1988 and 2003 that provide information on
K-ras mutations in hyperplastic and dysplastic duct
lesions in the pancreas. The described duct lesions
were reclassified according to the nomenclature for
pancreatic intraepithelial neoplasia (PanIN), and the
molecular methods for detecting K-ras were reviewed.
In PanIN lesions from pancreata of patients with PDAC,
there was a stepwise increase in K-ras mutations that
correlated with the grade of dysplasia of the PanIN
lesion. K-ras mutations were found in 36%, 44%, and
87% of PanIN-1a, 1b, and 2–3 lesions, respectively
(trend statistic P < .001). Mutation-enriched polymerase
chain reaction (PCR) resulted in higher rates of K-ras
mutations in PanIN than plain PCR did. The incidence
of K-ras mutations in PanIN lesions associated with
chronic pancreatitis (CP) or normal pancreas was low
(around 10%). In CP, K-ras mutations were only found
after a disease duration of 3 years. The correlation of
the incidence of K-rasmutations with the grade of dys-
plasia in PanIN and the occurrence of these mutations
in CP with a duration of more than 3 years underlines
the importance of this genetic change for the develop-
ment of PDAC.
Neoplasia (2005) 7, 17–23
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Introduction
Because of its late detection and poor response to therapy,
pancreatic ductal adenocarcinoma (PDAC) ranks as one of
the most lethal tumors [1]. Numerous genetic studies have
been conducted to identify a suitable marker for the early
recognition of PDAC [2,3]. This has resulted in the identifi-
cation of a number of PDAC-associated genes [4,5]. Among
these, the first gene studied in detail was the K-ras gene. It
soon turned out that in the majority of PDACs [6], it shows
mutations in a hot spot at codon 12, exon 1. When K-rasmuta-
tions were also found in in situ components of PDAC and
PDAC-associated duct lesions [7–9], they were thought to be
potential tumor precursors [10], and it was hoped that mutated
K-ras might serve as a marker of the developing PDAC [11].
However, further studies revealed K-ras mutations even in
the normal-appearing duct epithelium of the inflamed and
noninflammed non-neoplastic pancreas [12,13]. Similar results
were obtained in extrapancreatic adenocarcinomas, which
were also found to have an elevated K-ras mutation rate [14].
These findings reduced the significance of K-ras as a specific
tumor marker and raised the question of the role of K-ras in
pancreatic carcinogenesis. Another problem was that the fre-
quency of K-ras mutations found in duct lesions and PDACs
differed from study to study, most likely because of differences
in the molecular methodology [15] and the histopathologic
terminology used for the analyzed duct lesions.
The aim of this study was to determine if there is a corre-
lation between pancreatic intraepithelial neoplasia (PanIN) se-
verity and the frequency of K-ras mutation in patients with and
without PDAC by reviewing the published data on K-ras muta-
tions in duct lesions [16] using the new PanIN classification.
This recently proposed classification is based on the hypothesis
that hyperplastic pancreatic duct lesions have a preneoplastic
potential [10]. Hence, the duct lesions were given the name
PanIN. The designation seems to be correct because three
studies demonstrated an increase in loss of heterogeneity
(LOH) for p16, p53, and DPC4 according to the grade of
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dysplasia of the PanINs [17–19]. In order to make these
LOH data comparable to those of mutated K-ras in duct
lesions, we applied the PanIN classification to the old histo-
logic terms used to describe these lesions in the various
studies. We also included studies on patients with chronic
pancreatitis (CP) to find out whether the K-ras positivity rate
in the PanINs is similar to that in the PanINs associated
with PDACs.
We present a combined histopathologic and molecular
meta-analysis that attempts to better define the role that both
PanIN and K-ras may play in the pathogenesis of PDAC and
the progression of CP to PDAC.
Materials and Methods
Data Acquisition
The study was conceived as a histopathologic meta-
analysis [16]. We conducted a computer search of the Med-
line database for articles on K-ras mutations in pancreatic
duct lesions between 1988 and 2003. We evaluated only
studies published in peer-reviewed journals that presented
precise data on the histopathology of the duct lesions in the
form of either illustrations or detailed descriptions. Therefore,
short reports, abstracts, and conference reports, which are
usually included in the data acquisition of a meta-analysis,
were excluded [16]. Using search terms such as dysplasia,
hyperplasia,metaplasia, and intraductal tumor in conjunction
with pancreas and pancreatic, we identified 15 original con-
tributions with all the relevant information (Table 1). The way
the tissue was obtained (surgery, postmortem, and micro-
dissection), the associated condition (ductal adeno-
carcinoma, CP, and normal pancreas), and the polymerase
chain reaction (PCR) technique were recorded [15]. Duct
lesions reported in association with intrapancreatic mucinous
tumors (IPMTs) were excluded. A quality assessment proto-
col [20] was generated, defining the minimum criteria nec-
essary for a study to be included in the systematic review.
These were: 1) detailed histopathologic description of the
lesions; 2) histologic evidence of examples of such pancre-
atic lesions in printed figures; and 3) detection of K-ras
mutations. The suitability of a given paper for inclusion in
this study was assessed by two of the authors.
Evaluation of Histopathologic Data
On the basis of the PanIN classification, all studies with
histopathologic reports were reevaluated and the lesions
were classified [10,21] by two independent pathologists
(G.K. and J.L.) (Appendix 1).
Evaluation of Molecular Data
The PCR technique employed was characterized as
either plain PCR for K-ras without modification or mutation-
enriched PCR (ME-PCR) technique employing special
enzymes and/or PCR protocols [15]. Further, the method
used to verify PCR amplificates (restriction fragment length
polymorphism, direct DNA sequencing, and allele-specific
oligonucleotide hybridization) was recorded.
Statistical Analysis
We performed a meta-analysis of all the available
reports. The confidence interval estimates for the proportion
of K-ras–positive samples for each individual study and for
the overall estimates were calculated using Wilson’s method
[22]. For comparison of dichotomized stratified data, we
used the chi-square analysis. The Mantel-Haenszel test for
linear association was used to assess the significance of
the trend among strata. The exact Wilcoxon-Mann-Whitney
nonparametric test was used to compare the age distribu-
tion and the duration of CP with the presence or absence of
K-ras mutations.
Results
We identified 15 studies dealing with K-ras mutations in
pancreatic preneoplastic lesions that were histologically
defined. A total of 1519 lesions was included in these
studies. In all studies, it was possible to reclassify the
pancreatic duct lesions according to the PanIN classification
(Appendix 1).
The cases described as simple hyperplasia or mucous
hypertrophy corresponded well to PanIN-1A, and those
described as ductal papillary hyperplasia to PanIN-1B,
as shown by the figures in the various studies (Table 1).
The review of our own studies [9,17] also revealed a good
correlation between the old and new terminologies. Sixty-
one papillary lesions in CP with mild atypia were classified
as PanIN-1B. In a study by Yanagisawa et al. [23], histologic
illustrations of four lesions described as mucous papillary
hyperplasia revealed a high degree of nuclear atypia but
no structural abnormality. Hence, they were classified as
PanIN-2 lesions. In another investigation [7], six lesions were
typed as in situ carcinoma. They were accordingly classified
as PanIN-3 lesions.
A total of 908 lesions was classified as PanIN-1A, 476 as
PanIN-1B, 79 as PanIN-2, and 56 as PanIN-3. The overall
rate for K-ras mutations in PanIN lesions was 10% in CP
(95% CI, 7–14%) and 44% in PDAC (95% CI, 41–48%).
There was no correlation between K-ras positivity and the
source of the tissue.
The frequency of K-ras mutations in the PanIN lesions
varied considerably according to the underlying disease of
the patients (CP versus PDAC). Therefore, we investigated
the relation between K-ras mutations and the grade of the
PanIN lesions separately for each group of patients (PDAC,
CP, and normal) (Tables 1 and 2).
In patients with PDAC, the frequency of K-ras muta-
tions in the PanIN lesions increased with the PanIN
grade: 36% in PanIN-1A lesions, 44% in PanIN-1B lesions,
and 87% in PanIN-2–3 lesions (Table 2). Due to the rela-
tively small number of lesions, PanIN-2 and PanIN-3 lesions
were combined for statistical evaluation (Table 2). When
data from studies using plain PCR were compared with
data from studies using ME-PCR, it was found that the
latter technique was associated with a higher detection
rate of K-ras mutation in PanIN-IA and PanIN-IB lesions
(Table 2).
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Among patients with CP, the proportion of PanIN lesions
harboring K-ras mutations was relatively low (10%) and
independent of the PanIN grade of the lesion (Table 2). Here,
the ME-PCR techniques resulted in similar rates of K-ras
positivity in the PanIN-1A lesions and a higher percentage in
the PanIN-2–3 lesions. The number of lesions investigated
was too low in the ME-PCR group to result in any statis-
tically significant difference.
Only low-grade PanIN (1A/1B) lesions were reported in
the pancreas of patients free of pancreatic disease and,
again, a low proportion (11%) of these lesions harbored
K-ras mutations. There were no PanIN-3 lesions in patients
Table 1. Frequency of K-ras Mutations in PanIN Lesions in the Pancreas of Patients with PDAC (Upper Panel) or CP, or in Normal Disease-Free Pancreas
(Lower Panel).
Study Reference Patients** Lesions Method K-ras+/Total Foci K-ras+ (%)
Lemoine et al. (1992) [7] PDAC PanIN-1b PCR 0/9 0
PDAC PanIN-3 PCR 5/6 83
Motojima et al. (1993) [54] PDAC PanIN-3 PCR 2/2 100
Tabata et al. (1993) [55] PDAC PanIN-1a PCR 0/10 0
PDAC PanIN-2 PCR 5/6 83
Moskaluk et al. (1997) [8] PDAC PanIN-3 PCR 16/17 94
PDAC PanIN-1a PCR 2/7 29
Sugio et al. (1997) [56] PDAC PanIN-3 PCR 17/18 94
PDAC PanIN-2 PCR 19/23 83
PDAC PanIN-1a PCR 5/21 24
Z’graggen et al. (1997) [57] PDAC PanIN-1a PCR 3/11 27
Matsubayashi et al. (1999) [58] PDAC PanIN-1a Me-PCR 115/266 43
Terhune et al. (1998) [59] PDAC PanIN-1b Me-PCR 27/44 61
PDAC PanIN-3 Me-PCR 7/9 78
Lu¨ttges et al. (1999) [9] PDAC PanIN-1a PCR 33/123 27
PDAC PanIN-1b PCR 46/112 41
Mulligan et al. (1999) [60] PDAC PanIN-3 Me-PCR 3/4 75
Lemoine et al. (1992) [7] CP PanIN-1b PCR 0/5 0
Tabata et al. (1993) [55] CP PanIN-2 PCR 0/5 0
CP PanIN-1a PCR 0/5 0
Yanagisawa et al. (1993) [23] CP PanIN-2 PCR 1/4 25
CP PanIN-1a PCR 3/3 60
CP PanIN-1b PCR 6/7 86
Song et al. (1996) [61] CP PanIN-1b PCR 2/12 17
Rivera et al. (1997) [62] CP PanIN-1a PCR 2/11 18
Mulligan et al. (1999) [60] CP PanIN-2 Me-PCR 2/15 13
CP PanIN-1a Me-PCR 1/17 6
Lu¨ttges et al. (2000) [12] CP PanIN-2 PCR 0/26 0
CP PanIN-1a PCR 15/140 11
CP PanIN-1b PCR 4/97 4
Song et al. (1996) [61] Normal PanIN-1a PCR 1/3 33
Tada et al. (1996) [26] Normal PanIN-1a PCR 19/79 24
Matsubayashi et al. (1999) [58] Normal PanIN-1a Me-PCR 9/51 18
Terhune et al. (1998) [59] Normal PanIN-1b Me-PCR 8/17 47
Lu¨ttges et al. (1999) [9] Normal PanIN-1a PCR 10/153 7
Normal PanIN-1b PCR 6/173 3
Agoff et al. (2001) [63] Normal PanIN-1a PCR 0/8 0
In some studies, PanINs derived from both PDAC or CP were included but separately analyzed. Therefore, these studies appear twice.
*From patients with PDAC, CP, or without pancreas pathology (normal).
Table 2. PCR Data on K-ras Positivity in PanIN Lesions Associated with Various Pancreatic Disorders.
Technique Total
PCR Me-PCR
K-ras+/Total Foci K-ras+ % (95% CI) K-ras+/Total Foci K-ras+ % (95% CI) K-ras+/Total Foci K-ras+ % (95% CI)
PDAC
PanIN-1A 43/172 25 (19–32 ) 115/266 43 (37–49) 158/438 36 (32–41)
PanIN-1B 46/121 38 (29–47) 27/44 61 (46–75) 73/165 44 (37–52)
PanIN–2–3 67/76 88 (78–94) 7/9 78 (40–96) 74/85 87 (78–93)
Chronic pancreatitis
PanIN-1A 20/159 13 (8–19) 1/17 6 (0–31) 21/176 12 (8–18)
PanIN-1B 12/121 10 (5–17) – – 12/121 10 (5–17)
PanIN-2–3 1/35 3 (0–17) 2/15 13 (2–42) 3/50 6 (2–18)
Normal pancreas
PanIN-1A 30/243 12 (9–17) 9/51 18 (9–31) 39/294 13 (10–18)
PanIN-1B 6/173 3 (1–8) 8/17 47 (24–71) 14/190 7 (4–12)
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with CP. The numbers of PanIN-1A and PanIN-1B lesions
varied between the two PCRmethods; in the ME-PCR group,
the number of lesions was again low.
Using the original data reported in a previous study [12],
we investigated the possible effect of age and duration of CP
on the severity of PanIN lesions and on their K-ras status.
Among 25 patients with CP, we found no age difference
between those with PanIN-1A lesions (n = 4, median age =
47.5, range = 39–54) and those with either PanIN-1B (n = 8,
median age = 54.5, range = 30–69) or PanIN-2 lesions
(n = 13, median age = 50, range = 17–63; P = .59).
We also found no age difference between CP patients
with K-ras–negative PanIN lesions (n = 14, median age = 46,
range = 17–66) and those with K-ras–positive PanIN lesions
(n = 11, median age = 53, range = 33–69; P = .42).
Unlike patient’s age, the duration of CP was significantly
associated with K-ras positivity. Of the 16 CP patients for
whom information was available, the duration of CP for
the eight patients with K-ras–negative PanIN lesions was
shorter (median = 2 years, range = 0–17) than that of
the eight CP patients with K-ras–positive PanIN lesions
(median = 7.5 years, range = 3–34; P = .021) (Figure 1). No
case of CP with a disease duration of less than 3 years
showed K-ras mutations.
Discussion
Mutations in the K-ras oncogene are rare in the normal
disease-free pancreas [13]. Their frequency does not seem
to exceed 13% [15], whereas it reaches 80% in PDAC [24].
Our meta-analysis demonstrated that the frequency of K-ras
mutations in PanIN lesions corresponds to their grade of
dysplasia, with PanIN-2 and PanIN-3 lesions displaying a
significantly higher frequency (87%) than PanIN-1A (36%)
(Table 2). The second major finding was the correlation of
K-ras positivity in PanINs with the duration of CP.
We reviewed 15 studies and reclassified 1519 duct
lesions. In most studies, the duct lesions could be easily
reclassified, particularly when high-quality illustrations were
provided. Problems arose in about 15% of the studies. They
were due to uncommon phrasing of histopathologic findings
and concerned mostly the distinction of PanIN-2 lesions from
PanIN-3 lesions. Because of this occasional uncertainty and
the small total numbers of PanIN-2 and PanIN-3 lesions
reviewed, the statistical analysis was performed on a com-
bined PanIN-2/PanIN-3 group.
In an earlier study on the sensitivity of the molecular
method used for the detection of K-ras mutations and the
rate of positive samples [15], we already found that so-called
ME-PCR will result in higher rates of K-ras–positive samples
than plain PCR. This study confirmed this result and addi-
tionally showed that the high sensitivity of the ME-PCR
method was particularly evident in the low-grade PanINs.
Whether the results obtained with ME-PCR reflects the K-ras
mutation status better than plain PCR has been widely
debated during recent years [25]. However, in order to avoid
false-positive results as far as possible, the use of plain PCR
techniques with subsequent DNA sequencing appears to be
the method of choice.
Do K-ras mutations have a role as a diagnostic marker of
PDAC? Considering the methodological ambiguities and
the demonstration of K-ras positivity not only in CP but also
in the disease-free pancreas [12,13,26,27], the detection of a
K-rasmutation in a patient does not establish the diagnosis of
PDAC. However, the results of our meta-analysis show that a
K-ras mutation may be indicative of the development of a
PDAC, particularly in patientswithCP. The latter notionwould
be supported by our data that K-ras mutations were only
found in CP of more than 3 years’ duration. If, in addition, the
patient is a smoker, the risk would further increase. Under
these conditions as well as in surveillance programs for
patients with hereditary pancreatitis and familial pancreatic
carcinoma [28], K-ras analysis should be recommended.
This study clearly demonstrated that in PanINs from
patients with PDAC, the gradual increase in K-ras positivity
correlated with the grade of dysplasia. Other investigations
revealed a rising incidence of LOH for p16, p53, and DPC4/
SMAD4 with increasing PanIN grades [17,29]. In addition,
shortened telomeres have been demonstrated in PanIN
lesions of all grades [30] and were thought to predispose
PanINs to accumulate progressive chromosomal abnormal-
ities. Finally, BRCA2 and maspin, two tumor-suppressor
genes known to also be involved in breast tumorigenesis,
were found to be inactivated in PanIN-3 lesions [31,32].
Based on these findings [24,33–37], a progression model
for genetic alteration in PanINs has been proposed. In this
model, it is suggested that K-rasmutations occur early in the
evolution of PanINs [38].
Recently, new experimental evidence for the tumorigenic
potential of the ras oncogene was provided. Immortalization
of bovine pancreatic duct cells from the adult pancreas with
SV40 large-T and further transfection of mutated K-ras
resulted in a malignant phenotype. Upon transplantation into
nude mice, PDACs were formed [39]. In a three-step model,
Figure 1. Boxplot of the duration of CP with and without K-ras mutation.
Median duration for K-ras–negative patients = 2 years; K-ras–positive
patients = 7.5 years (P = .021).
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transfection of activated human telomerase (hTERT), SV40
large-T plus, and mutated H-ras drove human embryonic
kidney cells and fibroblasts into malignancy [40]. More
recently, in a study employing a conditionally transgenic
mouse model for K-ras, typical PanINs were induced in
animals with spontaneous progression to invasive ductal
adenocarcinoma [41]. Taken together, these data demon-
strate that ras does indeed play an important role in tumor-
igenesis and thus also in the pathogenesis of both PanINs
and PDAC. How, precisely, the activated K-ras alters the cell
machinery toward malignancy is not yet clear, but recent
studies suggest that K-ras stimulates cell proliferation rather
than inhibits apoptosis [36,42].
What may induce K-ras mutations in the pancreas? As
causes of K-ras mutations, smoking and also coffee con-
sumption have been discussed [27,43,44]. Whether the
same factors may also play a role in the induction of PanINs
is not known, but because PanIN-1 lesions may occur early
in life [13,45], it is possible that such K-ras–positive PanIN-1
lesions may exist for a long time. Eventually, one of them is
suddenly transformed into a higher-degree PanIN and inva-
sive PDAC by accidental accumulation of additional genetic
events genes such as p16, p53, and SMAD4/DPC4. Neither
the time axis of the progression nor the trigger for these
additional mutations is known. Recent findingsmay provide a
clue, at least in alcoholic CP: ethanol has a dramatic syner-
gistic effect with smoking on the formation of acetaldehyde
[46]. Acetaldehyde in turn generates reactive oxygen and
nitrogen species [47], resulting in reactive aldehydes, which
are known to induce DNA adducts and mutations [48]. Some
of the reactive aldehydes have been detected in CP already
[49]. Alkylating agents may induce specific K-ras mutations,
namely G–A transitions, as shown in those heavy smokers
in the absence of histologic lesions [27]. Besides alkylating
agents, methylating agents and organic solvents have been
demonstrated to induce K-ras mutations. Analyzing patients
with PDAC and occupational risks, these G–A transitions
could be associated with polycyclic aromatic hydrocarbons
and gasoline engine exhausts [50]. For methylating agents,
the proposed mechanism lies in the reduction of O6-alkyl
guanine DNA-alkyltransferase (MGMT), as shown in colo-
rectal adenomas [51]. Reduced MGMT has also been de-
scribed in PDAC [52]. The presumably long phase after the
first injury (K-ras) that makes the pancreatic duct epithelium
receptive to malignant transformation but unaltered—if not
injured for a second time—can be deemed as a ‘‘dance on
the volcano’’ that is harmless for most people but may be
fatal for a few [53].
In summary, using the new PanIN system, we reclassified
and then compared a large number of preneoplastic lesions
of varying grades in published reports. In PanINs associated
with PDAC, we found unambiguous evidence of a stepwise
increase in K-ras mutations with increasing grade of dys-
plasia. We also found that the duration of CP was signifi-
cantly longer in K-ras–positive than in K-ras–negative
patients and that the minimum duration of CP associated
with K-ras positivity was 3 years. These findings suggest that
K-ras mutations play an important role in the evolution of
PanINs and PDAC. However, detection of K-ras mutations
as the only test cannot be recommended as a screening tool
for PDAC but could be useful in combination with cytology.
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Appendix 1. Histopathologic description and grading of
PanIN
Normal: The normal ductal and ductular epithelium is a
cuboidal to low-columnar epithelium with amphophilic
cytoplasm. Mucinous cytoplasm, nuclear crowding, and
atypia are not seen.
Squamous (transitional) metaplasia: A process in which
the normal cuboidal ductal epithelium is replaced by
mature stratified squamous or pseudostratified transi-
tional epithelium without atypia.
PanIN-1A: These are flat epithelial lesions composed of
tall columnar cells with basally located nuclei and
abundant supranuclear mucin. The nuclei are small and
round to oval in shape. When oval, the nuclei are oriented
perpendicular to the basementmembrane. It is recognized
that theremay be considerable histologic overlap between
non-neoplastic flat hyperplastic lesions and flat neoplastic
lesions without atypia. Therefore, some may choose to
designate these entitles with the modifier term lesion
(‘‘PanIN/L-1A’’) to acknowledge that the neoplastic nature
of many cases of PanIN-1A has not been unambiguously
established.
PanIN-1B: These epithelial lesions have a papillary, mi-
cropapillary, or basally pseudostratified architecture but
are otherwise identical to PanIN-1A.
PanIN-2: Architecturally, these mucinous epithelial le-
sions may be flat but aremostly papillary. Cytologically, by
definition, these lesions must have some nuclear abnor-
malities. These abnormalities may include some loss of
polarity, nuclear crowding, enlarged nuclei, pseudo-
stratification, and hyperchromatism. These nuclear ab-
normalities fall short of those seen in PanIN-3. Mitoses
are rare but, when present, are nonluminal (not apical)
and are not atypical. True cribiform structures with luminal
necrosis and marked cytologic abnormalities are gener-
ally not seen and, when present, should suggest the
diagnosis of PanIN-3.
PanIN-3. Architecturally, these lesions are usually papil-
lary or micropapillary; however, they may rarely be flat.
True cribiforming, the appearance of ‘‘budding off’’ of
small clusters of epithelial cells into the lumen, and
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luminal necrosis should all suggest the diagnosis of
PanIN-3. Cytologically, these lesions are characterized
by a loss of nuclear polarity, dystrophic goblet cells (goblet
cells with nuclei oriented toward the lumen and mucinous
cytoplasm oriented toward the basement membrane),
mitoses that may occasionally be abnormal, nuclear
irregularities, and prominent (macro)nucleoli. The lesions
resemble carcinoma at the cytonuclear level, but invasion
through the basement membrane is absent.
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